Andrea Rockall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1566894/publications.pdf Version: 2024-02-01



ANDREA ROCKALL

#	Article	IF	CITATIONS
1	The impact of nutritional risk factors and sarcopenia on survival in patients treated with pelvic exenteration for recurrent gynaecological malignancy: a retrospective cohort study. Archives of Gynecology and Obstetrics, 2022, 305, 1343-1352.	0.8	7
2	O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee. Radiology, 2022, 303, 35-47.	3.6	57
3	O-RADS MRI Classification of Indeterminate Adnexal Lesions: Time-Intensity Curve Analysis Is Better Than Visual Assessment. Radiology, 2022, 303, 566-575.	3.6	16
4	Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC). British Journal of Cancer, 2022, 126, 1047-1054.	2.9	17
5	Optimal method for metabolic tumour volume assessment of cervical cancers with inter-observer agreement on [18F]-fluoro-deoxy-glucose positron emission tomography with computed tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2009-2023.	3.3	3
6	Adnexal Torsion: Review of Radiologic Appearances. Radiographics, 2021, 41, 609-624.	1.4	45
7	Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018. European Radiology, 2021, 31, 7802-7816.	2.3	71
8	Ovarian-Adnexal Reporting Lexicon for MRI: A White Paper of the ACR Ovarian-Adnexal Reporting and Data Systems MRI Committee. Journal of the American College of Radiology, 2021, 18, 713-729.	0.9	50
9	Correspondence on "ESGO/ISUOC/IOTA/ESGE consensus statement on pre-operative diagnosis of ovarian tumors" by Timmerman et al. International Journal of Gynecological Cancer, 2021, 31, 1394-1395.	1.2	1
10	Ovary: MRI characterisation and O-RADS MRI. British Journal of Radiology, 2021, 94, 20210157.	1.0	18
11	Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma. Clinical Cancer Research, 2021, 27, 6457-6466.	3.2	11
12	Authors' Response. Journal of the American College of Radiology, 2021, 18, 1594-1595.	0.9	2
13	Is tumour volume an independent predictor of outcome after radical prostatectomy for high-risk prostate cancer?. Prostate Cancer and Prostatic Diseases, 2021, , .	2.0	2
14	2018 FIGO Staging Classification for Cervical Cancer: Added Benefits of Imaging. Radiographics, 2020, 40, 1807-1822.	1.4	40
15	Predictors of patient preference for either whole body magnetic resonance imaging (WBâ€MRI) or CT/ PETâ€CT for staging colorectal or lung cancer. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 537-545.	0.9	8
16	Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival. Radiologia Medica, 2020, 125, 770-776.	4.7	26
17	Response Assessment and Follow-Up by Imaging in GYN Tumours. Medical Radiology, 2020, , 517-530.	0.0	Ο
18	Endometrial Cancer MRI staging: Updated Guidelines of the European Society of Urogenital Radiology. European Radiology, 2019, 29, 792-805.	2.3	166

ANDREA ROCKALL

#	Article	IF	CITATIONS
19	Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment. European Radiology, 2019, 29, 3889-3900.	2.3	20
20	A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nature Communications, 2019, 10, 764.	5.8	130
21	Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 455-466.	3.3	59
22	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. Health Technology Assessment, 2019, 23, 1-270.	1.3	34
23	European Society of Urogenital Radiology (ESUR) Guidelines: MR Imaging of Leiomyomas. European Radiology, 2018, 28, 3125-3137.	2.3	78
24	Perceived patient burden and acceptability of whole body MRI for staging lung and colorectal cancer; comparison with standard staging investigations. British Journal of Radiology, 2018, 91, 20170731.	1.0	23
25	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. British Journal of Radiology, 2018, 91, 20170577.	1.0	70
26	Can the completeness of radiological cancer staging reports be improved using proforma reporting? A prospective multicentre non-blinded interventional study across 21 centres in the UK. BMJ Open, 2018, 8, e018499.	0.8	20
27	Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. British Journal of Cancer, 2018, 119, 815-822.	2.9	35
28	Adnexal Diseases. IDKD Springer Series, 2018, , 75-84.	0.8	4
29	European society of urogenital radiology (ESUR) guidelines: MR imaging of pelvic endometriosis. European Radiology, 2017, 27, 2765-2775.	2.3	197
30	ESUR recommendations for MR imaging of the sonographically indeterminate adnexal mass: an update. European Radiology, 2017, 27, 2248-2257.	2.3	131
31	Patient experience and perceived acceptability of whole-body magnetic resonance imaging for staging colorectal and lung cancer compared with current staging scans: a qualitative study. BMJ Open, 2017, 7, e016391.	0.8	37
32	Diagnostic Value of MR Imaging in the Diagnosis of Adnexal Torsion. Radiology, 2016, 279, 461-470.	3.6	46
33	Functional MR Imaging in Gynecologic Cancer. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 205-222.	0.6	21
34	A framework for optimization of diffusion-weighted MRI protocols for large field-of-view abdominal-pelvic imaging in multicenter studies. Medical Physics, 2015, 43, 95-110.	1.6	33
35	Cross-Sectional Imaging of Neuroendocrine Tumours. , 2015, , 97-129.		0
36	Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies Journal of Clinical Oncology, 2015, 33, 2514-2514.	0.8	5

ANDREA ROCKALL

#	Article	IF	CITATIONS
37	A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers Journal of Clinical Oncology, 2015, 33, 2547-2547.	0.8	3
38	Neoplasms of the Ovary. , 2015, , 129-158.		0
39	Imaging techniques for the pre-surgical diagnosis of adnexal tumours. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2014, 28, 683-695.	1.4	46
40	Functional Imaging to Predict Tumor Response in Locally Advanced Cervical Cancer. Current Oncology Reports, 2013, 15, 549-558.	1.8	43
41	The MRI features of histologically proven ovarian cystadenofibromas—an assessment of the morphological and enhancement patterns. European Radiology, 2013, 23, 48-56.	2.3	24
42	Adnexal Masses: Development and Preliminary Validation of an MR Imaging Scoring System. Radiology, 2013, 267, 432-443.	3.6	176
43	Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead. Neuroendocrinology, 2012, 96, 261-271.	1.2	51
44	Radiological manifestations of metastasis to the ovary. Journal of Clinical Pathology, 2012, 65, 585-590.	1.0	27
45	New ways of assessing ovarian cancer response: metabolic imaging and beyond. Cancer Imaging, 2012, 12, 310-314.	1.2	14
46	Radiological appearances of gynaecological emergencies. Insights Into Imaging, 2012, 3, 265-275.	1.6	60
47	Effectiveness of semi-quantitative multiphase dynamic contrast-enhanced MRI as a predictor of malignancy in complex adnexal masses: radiological and pathological correlation. European Radiology, 2012, 22, 880-890.	2.3	82
48	Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression Journal of Clinical Oncology, 2012, 30, 388-388.	0.8	4
49	The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer Journal of Clinical Oncology, 2012, 30, 427-427.	0.8	5
50	Can quantitative dynamic contrast-enhanced MRI independently characterize an ovarian mass?. European Radiology, 2010, 20, 2176-2183.	2.3	42
51	Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. European Journal of Endocrinology, 2010, 162, 1165.	1.9	1
52	The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging in the female pelvis. European Journal of Radiology, 2010, 76, 367-385.	1.2	164
53	Cushing's syndrome caused by an occult source: difficulties in diagnosis and management. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 642-647.	2.9	35

54 Functional imaging: from tumour biology to the clinic. , 0, , 183-202.

0